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Background: Optimal debulking surgery is postulated to be useful in survival of ovarian cancer patients. Some
studies highlighted the possible role of bowel surgery in this topic. We wanted to evaluate the role of bowel
involvement in patients with advanced epithelial ovarian cancer who underwent optimal cytoreduction.
Methods: Between 1997 and 2004, 301 patients with advanced epithelial cancer underwent surgery at Department
of Gynecological Oncology of Centro di Riferimento Oncologico (CRO) National Cancer Institute Aviano (PN) Italy.
All underwent maximal surgical effort, including bowel and upper abdominal procedure, in order to achieve
optimal debulking (R < 0.5 cm). PFS and OS were compared with residual disease, grading and surgical procedures.
Results: Optimal cytoreduction was achieved in 244 patients (81.0%); R0 in 209 women (69.4.%) and R < 0.5 in 35
(11.6%). Bowel resection was performed in 116 patients (38.5%): recto-sigmoidectomy alone (69.8%), upper bowel
resection only (14.7%) and both recto-sigmoidectomy and other bowel resection (15.5%). Pelvic peritonectomy and
upper abdomen procedures were carried out in 202 (67.1%) and 82 (27.2%) patients respectively. Among the 284
patients available for follow-up, PFS and OS were significantly better in patients with R < 0.5. Among the 229
patients with optimal debulking (R < 0.5), 137 patients (59.8%) developed recurrent disease or progression. In the
229 R < 0.5 group, bowel involvement was associated with decreased PFS and OS in G1-2 patients whereas in G3
patients OS, but not PFS, was adversely affected. In the 199 patients with R0, PFS and OS were significantly better
(p < 0.01) for G1-2 patients without bowel involvement whereas only significant OS (p < 0.05) was observed in G3
patients without bowel involvement versus G3 patients with bowel involvement.
Conclusions: Optimal cytoreduction (R < 0.5 cm and R0) is the most important prognostic factor for advanced
epithelial ovarian cancer. In the optimally cytoreduced (R < 0.5 and R0) patients, bowel involvement is associated
with dismal prognosis for OS both in patients with G1-2 grading and in patients with G3 grading. Bowel involvement
in G3 patients, carries instead the same risk of recurrence for PFS.
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Epithelial Ovarian cancer is the leading cause of death
from gynaecological malignancies in the Western World
[1]. Cytoreductive surgery followed by paclitaxel/platinum
based chemotherapy represents the standard treatment
for patients with advanced disease, and the addition of
concomitant and sequential bevacizumab to chemother-
apy seems to further improve the clinical outcome [2-11].
The definition of optimal surgical cytoreduction has
evolved from residual disease ≤ 1 cm to no gross residual
disease, since there is a growing body of evidence that pa-
tients with no macroscopic residuum have better survival
than those with optimal but visible residual disease [10].
Therefore aggressive surgical procedures, such as radical
pelvic resection with retroperitoneal approach and exten-
sive upper abdominal procedures, are more and more in-
creasingly performed [12-25]. Eisenhower et al. [17], who
retrospectively assessed a cohort of 262 patients with
stage IIIc-IV epithelial ovarian cancer treated at the Me-
morial Sloan-Kettering Cancer Center, found that women
requiring extensive upper abdominal procedures to achieve
optimal cytoreduction had a similar response rate,
progression-free survival, and overall survival when
compared to women optimally cytoreduced by standard
surgical techniques. Rectosigmoid resection is often re-
quired during primary surgery of advanced epithelial
ovarian cancer, and a primary reanastomosis is possible
in more than 80% of the cases [12,13,15,18-21,23,24],
According to several authors rectosigmoid- colectomy
may significantly improve both the chance of optimal
cytoreduction and the clinical outcome of patients with
epithelial ovarian cancer [14,20,23,26,27]. On the other
hand, Jager et al. [28] assessed 194 women with stage III
disease who underwent primary surgery, and confirmed
that the complete removal of macroscopic tumor of-
fered the best overall survival, but reported that, when-
ever the bowel was involved, even maximum bowel
resections did not prolong survival compared to pa-
tients with residual disease after surgery.
The aim of this study was to evaluate the impact of
complete cytoreduction in advanced epithelial ovarian
cancer on recurrence rate and survival, focusing on the
prognostic impact of bowel involvement.
Methods
Patients
This retrospective study was conducted on patients with
advanced epithelial ovarian cancer (stage III and IV)
who underwent cytoreductive surgery (either primary
surgical cytoreduction or interval debulking surgery after
3–4 cycles of neoadjuvant chemotherapy) at Department
of Gynecological Oncology of Centro di Riferimento
Oncologico (CRO) National Cancer Institute Aviano
(PN) Italy, between January 1997 and December 2004.Patients with borderline ovarian tumor were excluded
from whole analysis and patients with sub-optimal debulk-
ing or lost to follow-up were excluded from survival ana-
lysis. At the National Cancer Institute, according to the
guidelines of the local ethics committee, before surgery,
every patient signs an informed consent to use tissue and
clinical record.
Analysis of sugical procedures
All patients underwent longitudinal laparotomy from
epigastrium to pubic bone. If present, ascites was collected
for cytological examination or otherwise washing of the
peritoneal cavity was performed. After inspection and pal-
pation of the entire abdominal-pelvic cavity, the surgeon
decided if surgical debulking was achievable. In this case,
total hysterectomy, bilateral salpingo-oophorectomy and
radical omentectomy were carried out. In presence of in-
volvement of the cul-de-sac or vesico-uterine fold as well
as of a frozen pelvis, a pelvic retroperitoneal approach was
used, and when necessary, a rectosigmoid resection was
performed through a mesorectal excision. Primary reanas-
tomosis was attempted whenever possible; if this proced-
ure was deemed unsafe, a colostomy was done. In order to
achieve optimal residual disease, retroperitoneal lymphad-
enectomy was performed in case of bulky or suspicious
nodes. Pelvic lymphadenectomy was performed from in-
guinal ligament up to common iliac vessels, while caval
and aortic lymphadenectomy was performed up to the
level of left renal vein. In order to remove all macroscopic
lesions in upper abdomen, upper abdominal surgical pro-
cedures, including diaphragmatic peritoneum stripping,
diaphragmatic full-thickness resection, liver metastasect-
omy, cholecystectomy, partial gastrectomy, distal pancrea-
sectomy, splenectomy and bowel resections, were carried
out.
The tumor stage and histological diagnosis of each case
were determined according to FIGO criteria and the histo-
logical typing system of the World Health Organization,
respectively. Tumors were graded as well (G1), moderately
(G2), or poorly (G3) differentiated.
Postoperative residual disease was classified as R0 (no
macroscopic residual tumor), R < 0.5 (residual tumoral
nodules ≤0.5 cm), and R2 (residual tumoral nodules >
0.5 cm). Optimal cytoreduction was defined as residual
disease ≤ 0.5 cm (R0 or R < 0.5).
Intra-operative and post-operative (within 30 days) com-
plications were recorded.
All patients received postoperative platinum- based
chemotherapy, and were periodically monitored after-
wards. During primary chemotherapy routine CA125
assessement was made before every chemotherapy cycle
while physical examination and CT scan were performed
after three cycles only if residual tumor was left following
debulking surgery (R < 0.5 and R2 patients). In the first
Table 1 Patient characteristics of the 301 patients with
advanced ovarian epithelial cancer
Characteristics n/N %















Ascites > 500 ml 62/301 20.6%
Primary Cytoreductive Surgery 240/301 79.7%
Interval Debulking Surgery 61/301 20.3%
Residual Disease after surgery
R0 209/301 69.4%
R < 0.5 35/301 11.6%
R2 57/301 19%
R0 in G3 130/208 62.5%
R0 in G1-2 79/93 84.9%
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dominal ultrasonography were alternatively performed
every other 6 months (in order to perform an imaging
examination every three months), serum CA 125 assay,
and physical examination were performed every three
months. After two years the examination schedule was
halved. Further investigations (PET scan, MRI, colonscopy,
etc.) were performed when appropriate. An asymptomatic
patient with rising CA125 levels and negative clinical and
imaging examinations was still considered not to have re-
current disease and underwent only a more stringent
follow-up programme.
Statistical analysis
All data were analyzed using SPSS 13.0. The interval
time from surgery to progression or last observation was
defined as the progression free survival (PFS Progression
Free Survival), and interval time from surgery to death
or last observation was defined as the overall survival
(OS Overall Survival).
The cumulative probability of PFS and OS were esti-
mated by the product-limit method. The log-rank test
was used to compare the homogeneity of PFS and OS
functions across strata defined by categories of prognos-
tic variables. A multiple regression analysis based on the
Cox proportional hazard model was used to jointly test
the relative importance of variables as predictors of PFS
and OS. Confidence Interval (C.I.) and hazard ratio (HR)
was reported when appropriate. Non-parametric values
were compared with χ2 test. Statistical significance was
set at p < 0.05.
Results
Patients
Three hundred and twelve patients with advanced stage
ovarian cancer as defined in Methods section were se-
lected. Eleven patients with adavanced Border Line neo-
plasia were excluded from analysis. The characteristics
of the remaining 301 patients are reported on Table 1.
Treatment results
Surgical procedures in the 301 patients with advanced
epithelial ovarian cancer are reported on Table 2. An
overall optimal cytoreduction was achieved in 244/301
patients (81.0%).
In the group of primary cytoreduction, 190/240 patients
(79.2%) achieved optimal debulking (R0 163/190 85.8%,
R < 0.5 27/190 14.2%), while in the group of interval
debulking surgery, 54/61 patients (88.5%) achieved opti-
mal debulking (R0 46/54 85.2%, R < 0.5 8/54 14.8%), (p
N.S.). Primary reanastomosis was performed in 95 out
of the 99 patients who underwent a recto-sigmoid resec-
tion, whereas a colostomy was needed in only 4 women
(4.0%).The median operating time was 200 minutes (range,
120 to 560 minutes). The median hospital stay was 12
days (range 6 to 51 days ). Sixty-nine out of 301 patients
(22.9%) received blood transfusion, with a median of 2
transfused units (range 1–7).Complications
Major intra-operative complications occurred in 44/301
patients (14.6%) (Table 3). All these lesions were immedi-
ately repaired and healed with no further complications.
Twenty-eight patients (9.3%) had major perioperative com-
plications, and are reported on Table 3; three patients had
more than one complication. Pulmonary embolism oc-
curred only in patients who underwent bowel resection.
Lymphocysts were diagnosed by ultrasound examination
in 32 of the 196 patients (16.3%) who underwent lymphad-
enectomy after 14–30 days from surgery. An ultrasound-
guided drainage was needed only in 6 cases. Thirty-five
(11.6%) patients experienced prolonged ileus (more than
10 days) which was treated conservatively.
Table 2 Surgical procedures of the 301 patients with
advanced ovarian epithelial cancer
Bowel Resection 116/301 38.5%
Rectosigmoidectomy Only 81/116 69,8%




Pelvic Peritonectomy Only 133/301 44,2%




Upper Abdominal Procedures 82/301 27.2%
Diaphragmatic Peritoneum Stripping 45/82 54,9%
Splenectomy 31/82 37,8%
Colecystectomy 16/82 19,5%
Liver Metastasectomy 5/82 6,1%
Partial Gastrectomy 3/82 3,6%
Distal Pancreatectomy 3/82 3,6%
Diaphragmatic Full-Thickness Resection 2/82 2.4%
Hepatic Hilum Lymphadenectomy 1/82 1.4%
Celiac Lymphadenectomy 1/82 1.4%
Retroperitoneal Lymphadenectomy 196/301 65.1%
Pelvic Lymphadenectomy 188/196 95.9%
Aortic Lymphadenectomy 149/196 74.5%
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Seventeen patients were lost to follow-up. Two-hundred
and eighty-four patients were followed until they died or
until December 2009. The median follow-up of 138 survi-
vors was 67 months (range 12–120 months). Of these 284
patients, 229 had optimal residual disease (80.3%) and 109
had bowel resection (38.4%). Of the 109 patients with
bowel involvement, 45/109 (41.3%) had infiltration of in-
testinal serosa, 48/109 (44.0%) had infiltration of muscularTable 3 Postoperative major complications in patients with b
Total (n = 301) Bowel resec
Intraoperative complications
Vessel injuries 8 (2.7%)
Bladder lesions 24 (8.0%)
Diaphragm perforations 12 (4.0%)
Estimated blood loss ≥ 1000 mL 65 (21.6%)
Perioperative complications
Wound infection 5 (1.7%)
Pleuric effusion 5 (1.7%)
Post-operative hemorrhage 4 (1.3%)
Enteric fistula 10 (3.3%)
Pulmonary embolism 3 (1.0%)
Pelvic Infection 4 (1.3%)intestinal layer, and 16/109 (14.7%) had infiltration of in-
testinal mucosa.
PFS and OS were significantly better for patients with
optimal residual disease (R0 and R < 0.5) than in those
with suboptimal residual disease (R2): median PFS, 34
months (95% C.I. 21.9-46.0) versus 16 months (95% C.I.
10.5-21.5), (p <0.01), and median OS, 90 months (95% C.I.
64.3-115.6) versus 42 months (95% C.I. 21.1-62.9) (p <
0.01).
In the subsequent analyses only the group of 229 pa-
tients with optimal debulking were evaluated. Of the pa-
tients with optimal debulking 75/229 (32.7%) had bowel
resection, 137/229 (59.8%) developed recurrent disease
or progression and 65/137 (47.4%) of these underwent
secondary surgery with cytoreductive intent. Nineteen
out of 229 patients (8.2%) developed metacronous liver
metastasis: 9/75 in the group with bowel involvement
(12.0%) and 7/154 in the group without bowel involve-
ment (4.5%) (p <0.05).
In the group of 229 patients with optimal residual dis-
ease, PFS (Figure 1A) and OS (Figure 1B) were signifi-
cantly lower in patients who underwent bowel resection
than in those who did not. Of the 229 patients with opti-
mal residual disease, 148/229 (64.6%) had G3 tumor and
81/229 (35.4%) had G1-G2 tumor. Among the patients
with G3 tumor, PFS was similar in women with bowel re-
section and in those without bowel resection (Figure 2A).
The OS (Figure 2B) was instead significantly better for pa-
tients who did not need bowel resection to achieve opti-
mal debulking. Among the patients with G1-G2 tumor,
both PFS (Figure 3A) and OS (Figure 3B) were signifi-
cantly lower in women who underwent bowel surgery
compared to those who did not. Cox model showed that
only tumor grade (G3 versus G1-G2), primary cytoreduc-
tive surgery and residual disease after surgery (Absent re-
sidual disease R0 versus Residual Tumor present although
less than 0.5 cm) were independent prognostic variablesowel resection and in those without bowel resection
tion group (n = 116) No resection group (n = 185) p
3 (2.6%) 5 (2.7%) NS
14 (12.1%) 10 (5.4%) <0.05
8 (6.9%) 4 (2.2%) <0.05
37 (31.9%) 28 (15.1%) <0.05
4 (3.4%) 1 (0.5%) NS
4 (3.4%) 1 (0.5%) NS
3 (2.6%) 1 (0.5%) NS
5 (4.3%) 5 (2.7%) NS
3 (2.6%) 0 <0.05

















































Log Rank X2=14.84 p<0.01
B
Figure 1 Comparison between patients who underwent bowel resection (red line) and patients who did not (blue line). Median PFS (A),
22 months (95% C.I. 14.8-29.1) versus 49 months (95% C.I. 31.0-66-9), (p < 0,01) and median OS (B), 38 months (95% C.I. 24.0-51.9) versus 120
months (95% C.I. not evaluable), (p < 0.01).
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dominal surgery were not. As far as OS is concerned,
age, tumor grade, primary cytoreductive surgery and





















Log Rank X2=0.41 p N.S.
A
Figure 2 Comparison between G3 patients who underwent bowel res
(A), 22 months (95% C.I. 10.3-33.7) versus 27 months (95% C.I. 20.3-33.7), (p
months (95% C.I. 25.9-50.1), (p < 0.05).So, by analyzing the group of 199 patients with no re-
sidual disease after surgery (R0), and grouping them by
grading and intestinal resection, it was noticeable that
only patients with G1 or G2 tumor and without bowel
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B
ection (red line) and patients who did not (blue line). Median PFS









































Log Rank X2=5.48 p<0.05
B
Figure 3 Comparison between G1-2 patients who underwent bowel resection (red line) and patients who did not (blue line). Median
PFS (A) 25 months (95% C.I. 10.6-39.5) versus median not reached (mean 87.6 months), (p < 0.01), and median OS (B), 80 months (95% C.I. 2.0-157.9)
versus median not reached (mean 101.4 months), (p < 0.05).
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difference observed was between the patients with G3
tumor with and without bowel involvement (p < 0.05)
(Figure 4). Cox model in the R0 patients showed that only
tumor grade (G3 versus G1-G2), and primary cytoreduc-
tive surgery were independent prognostic variables for
PFS (p < 0.01), whereas bowel surgery and upper abdom-
inal surgery were not. As far as OS is concerned, age,
tumor grade, and primary cytoreductive surgery were in-
dependent prognostic variables (p < 0.01) (Table 4). In this
R0 group 46 out of 123 G3 patients (37.4%) had bowel in-
volvement (and therefore resection) while 14 out of 76
G1-2 patients (18.4%) had bowel involvement (p <0.01).
Discussion
The meta-analysis of data from 53 studies including
6,885 patients with stage III-IV epithelial ovarian cancer
who underwent cytoreductive surgery followed by cis-
platin or carboplatin-based chemotherapy showed that
percent maximal cytoreduction was an independent
prognostic variable for survival (P <0.001) [2]. Each 10%
increase in maximal cytoreduction was associated with a
5.5% increase in median survival. It is noteworthy that
median survival time was 23.0 months for patients who
had maximal cytoreductive surgery rate of 25% or less
compared to 36.8 months for those in which maximal
cytoreductive surgery was achieved in more than 75% of
cases. The present study confirms that optimal surgical
cytoreduction is the most important prognostic factor
for advanced epithelial ovarian cancer [2-5,7,10,17]. All
attempts should be made to achieve complete cytore-
duction, but when this result is not achievable, thesurgical goal should be al least a residual disease < 1 cm
[7]. Optimal cytoreduction can be often obtained even in
patients with large tumor volumes or with stage IV disease
[5,17]. Data from the literature showed that women oper-
ated by physicians with training in gynaecological oncol-
ogy have a significant survival advantage when compared
to those operated by general surgeons or generalist gynae-
cologists, thus suggesting that centralization of epithelial
ovarian cancer surgery might improve the clinical out-
come [26]. In the current series, optimal cytoreduction,
defined as residual disease ≤ 0.5 cm, was achieved in 81%
and R0 in 69.4% of 301 women with stage III-IV epithelial
ovarian cancer. The performance of recto-sigmoid colon
resection in patients with bulky pelvic disease is rational,
because the distal sigmoid is frequently involved through
either direct extension or serosal implantation from epi-
thelial ovarian cancer, and this surgical procedure may
contribute to achieve a complete primary cytoreduction
with an acceptable peri-operative morbidity [12,13,15,18-21,
23,24]. Mourton et al. [18] retrospectively assessed 58 pa-
tients who underwent en bloc resection with low recto-
sigmoid resection and anastomosis without protective
ileostomy, and found an anastomotic leakage requiring
colostomy only in one case (1.7%) and a pelvic abscess
only in 3 cases (5%). In the series of Park et al. (22) , the
complications associated with low anterior en bloc resec-
tion as part of cytoreductive surgery occurred in 2 out of
60 patients (one leakage of anastomosis site and one rec-
tovaginal fistula), and both were managed with diversion
colostomy. Among the 238 patients included in the study
of Peiretti et al. [24], an anastomotic leakage and a pelvic
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Log Rank X2=30.2 p<0.01
Log Rank p N.S.
B
Figure 4 Comparison among patients with G1-2 tumor and no bowel resection (blu line), patients with G-1 tumor and bowel resection
(green line), patients with G3 tumor and no bowel resection (red line), and patients with G3 tumors and bowel resection (black line).
G1-2 without bowel resection (62/199 31.2%): median PFS (A) not reached (mean 91.2), median OS (B) not reached (mean 103.9). G1-2 with
bowel resection (14/199 7.0%): median PFS (A) 25,0 months (95% C.I. 0–51.8), median OS (B) 46.0 months (95% C.I: 0–106.3). G3 without bowel
resection (77/199 38.7%): median PFS (A) 27,0 months (95% C.I. 20,3-33.7), median OS (B) 85.0 months (95% C.I. 51,6-116.3). G3 with bowel
resection (46/199 23.1%) median PFS (A) 27.0 months (95% C.I. 11,4-42.6) median OS (B) 38.0 months (95% C.I. 28,8-47.2). Patients with G1-2
tumor and without bowel involvement had a better prognosis for both PFS and OS (p < 0.01). Patients with G3 tumor without bowel
involvement had a better OS versus G3 patients with bowel involvement (p < 0.05).
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section was performed in 99 patients, with acceptable
perioperative and postoperative complications. The most
common bowel-related morbidity was prolonged ileus,
followed by enteric fistula. Jaeger et al. [28] reported that
bowel involvement in epithelial ovarian cancer had a bad
prognosis and that survival could not substantially be im-
proved by bowel resection, independently from the re-
sidual disease achieved. Conversely, according to other
authors, rectosigmoid colectomy may improve the clinical
outcome of these patients [14,20,23,26]. Aletti et al. [21],
retrospectively assessed 209 patients who had tumorTable 4 Estimates of Cox proportional hazard model in R0 pa
R
Coe
Infiltration of Mucosa or Muscolar layer vs. Infiltration of Serosa
Intestinal Resection vs. No Intestinal Resection
Grading G 1&2 vs 3
Upper Abdominal Procedures vs. No Upper Abdominal Procedures
Age
Primary Cytoreduction vs. Interval Debulking Surgeryinvolving the peritoneum of the cul-de-sac at the time of
primary surgery, and reported that women managed with
either stripping of the peritoneum (n = 77) or rectosig-
moid colectomy (n = 57) had improved 5-year overall sur-
vivals when compared to those who underwent none of
these procedures (n = 75) (37% versus 39% versus 6%; p <
0.0001). Among patients with no macroscopic residual
disease, 5-year survival was significantly better for those
managed with rectosigmoid colectomy than for those
treated with pelvic peritonectomy (89% versus 50%, p =
0.04). Conversely, Galotta et al. [23] reported a similar
mean overall survival in the 71 patients who underwenttients
egression
fficient (B) PFS
PFS (p) PFS HR Regression
Coefficient (B) OS
OS (p) OS HR
-,502 ,234 ,605 -,271 ,458 ,763
-,152 ,942 ,859 -,404 ,184 ,668
,974 ,000 2,648 ,784 ,004 2,189
-,499 ,119 ,607 -,409 ,127 ,664
,005 ,335 1,005 ,039 ,000 1,040
1,277 ,000 3,586 1,280 ,000 3,596
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underwent pelvic peritonectomy (38.8 versus 48.2 months,
p = 0.122) during an optimal en bloc tumor resection.
So it seems that, despite the acceptable morbidity, the
clinical relevance of bowel resection for cytoreductive
surgery is controversial because of the lack of uniform
data showing improved survival.
In the present investigation the analysis of the patients
with R < 0.5 showed that, in the subset of women with
G3 tumor, PFS was similar for patients who underwent
bowel resection and for those who did not, although OS
seemed to be jeopardized by bowel involvement. How-
ever, in the subset of R0 patients only G1-2 patients
without bowel involvement had an excellent prognosis,
whereas there was no statistical difference in PFS among
the group of G3 patient (with and without bowel resec-
tion) and the group of G1-2 patient with bowel resec-
tion. The difference was only in OS between G3 patients
with and without bowel involvement. Moreover it seems
that bowel involvement is a poor prognostic sign and
that aggressive surgery, leading to R0, is effective in im-
proving recurrence but not survival. In our patients
multivariate analysis revealed that Grading (G1-2 versus
G3) and not bowel involvement was a significant inde-
pendent variable, whereas in the study of Jaeger [28] the
findings were different. The important differences be-
tween the two studies are the number of G3 patients
(69% in our study vs 50% in Jager paper) and the R0 pa-
tients with initial bowel involvement (30.1% in our study
versus 15.8% in Jaeger paper), and the fact that in our
study G1 and G2 patients were grouped together vs. G3
patients. Moreover, in our study, bowel involvement was
significantly associated with G3 status (85.9% vs. 53.1%).
Therefore in patients with G3 tumor, bowel resection
appears to give only limited clinical benefit. If surgical
procedure leads to R0 or R < 0.5, the patients have the
same risk of recurrence as the patients in whom an opti-
mal debulking is obtained with a less aggressive surgery.
However, an aggressive tumor invading bowel and re-
quiring bowel resection to achieve optimal debulking
could be less responsive to salvage treatment after recur-
rence, as for instance, a significant difference in metacro-
nous hepatic mestastis was observed (12.0% in patients
with bowel involvement versus 4.5%). This could explain
why the positive effect of bowel surgery in terms of PFS
does not translate into a benefit in terms of OS. Con-
versely, among the optimally cytoreduced women with
G1-G2 tumor, PFS and OS were lower for women who
had bowel surgery compared to those who had not. These
results resemble those obtained by Jaeger [28] but with
some differences. The level of optimal debulking in our
population was set at residual disease of <0.5 cm (instead
of <2 cm) and G3 tumor were more represented (69.1%
versus 50.0%). Nevertheless, comparing the groups ofpatients with R0 in univariate analysis, OS was also better
for G3 patients without bowel involvement versus G1-2
patients with bowel involvement. In multivariate analysis
instead, Grading and not bowel surgery (that is bowel in-
volvement) was the independent prognostic variable, both
in the 229 R < 0.5 patients and in the 199 R0 patients. In
fact, as stated before, there was a close relationship be-
tween G3 and bowel involvement.
Conclusions
In conclusion, an aggressive surgical behavior including
bowel resection and leading to optimal cytoreduction
has a favorable impact on PFS and OS. However, in the
group of patients with optimal cytoreduction, bowel in-
volvement carries a negative prognostic value (for both
PFS and OS) especially in G1-2 patients. Thus, G1-2 pa-
tients without bowel involvement could represent in fact
a different population with an excellent prognosis.
In G3 patients, bowel involvement is again a bad prog-
nostic sign, since radical surgery seems to mitigate the in-
trinsic biological aggressiveness of G3 tumor only for PFS.
The currently accepted dualistic model for the patho-
genesis of epithelial ovarian cancer subdivides this ma-
lignancy into two categories termed type I and type II
[29,30]. Type I tumours (that include low-grade serous
carcinoma, low-grade endometrioid carcinoma, clear cell
carcinoma, mucinous carcinoma and Brenner tumour)
usually have an indolent clinical behaviour, are often de-
tected in early stage, rarely harbour p53 gene mutations,
and are genetically stable, but each histological type has
a distinct molecular profile, with mutations of genes in-
volved in different signalling transduction pathways. Type
II tumours (including high-grade serous carcinoma, high-
grade endometrioid carcinoma, undifferentiated carcin-
oma and carcinosarcoma) have a very aggressive biological
behaviour, are usually in advanced stage at presentation,
often harbour p53 gene mutations, and are genetically
unstable.
Further multicenter studies on larger series of patients
(in order to include more G1-2 patients or alternatively
Type I ovarian tumor) are required to clarify whether the
bowel involvement has a different impact on the clinical
outcome of patients with different biological types of epi-
thelial ovarian cancer in face of aggressive surgery with
optimal debulking.
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